Peginterferon alfa-2a (Pegasys)

From - A Hematology Oncology Wiki
Jump to navigation Jump to search

General information

Class/mechanism: Immune system activator; binds to human type 1 interferon, activating downstream intracellular signal transduction pathways initially mediated by the JAK/STAT pathway. Interferon α-2a activates multiple biologic effects which are not fully understood. Pegylation results in a much longer half-life compared to Interferon alfa-2a (Roferon-A).[1][2]
Route: SC
Extravasation: n/a

For conciseness and simplicity, currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

Diseases for which it was used

Patient drug information

History of changes in FDA indication

  • 2002-10-16: Initial approval for the treatment of adults with chronic hepatitis C who have compensated liver disease and have not been previously treated with interferon alfa.

History of changes in EMA indication

  • 2001-07-05: EURD

Also known as

  • Brand name: Pegasys